Solutia Reports Third Quarter 20...(283 94 Selling general and...)

Date:10/26/2009

283 94 Selling, general and administrative expenses 157 164 42 Research, development and other operating expenses, net 14 4 3 --- --- --- Operating Income 168 115 49 Interest expense (a) (98) (107) (21) Other income (loss), net (3) 13 3 Reorganization items, net -- -- 1,433 --- --- ----- Income from Continuing Operations Before Income Tax Expense 67 21 1,464 Income tax expense 15 17 214 --- --- --- Income from Continuing Operations 52 4 1,250 Income (Loss) from Discontinued Operations, net of tax (169) (52) 204 ----- ---- --- Net Income (Loss) (117) (48) 1,454 Net Income attributable to noncontrolling interest 3 5 -- --- --- --- Net Income (Loss) attributable to Solutia $(120) $(53) $1,454 ====== ===== ====== Basic and Diluted Income (Loss) per Share: Income (Loss) from Continuing Operations attributable to Solutia $0.48 $(0.01) $11.96 Income (Loss) from Discontinued Operations (1.65) (0.78) 1.95 ------ ------ ---- Net Inc
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009